NovaBridge Biosciences
NBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001778016
In the last 90 days, NovaBridge Biosciences insiders filed 0 open-market purchases and 4 sales; 49 institutions reported holding it in 13F filings for Q2 2026, worth $48.1M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $92.3K in total
- 4
- 13F holdersQ2 2026, +2 vs. previous quarter
- 49
- 13F valueReported value at the end of Q2 2026
- $48.1M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding NBP, Q2 2026
1 superinvestor reports holding NovaBridge Biosciences on Form 13F. Percentages are the stock's share of each portfolio.
HHLR Advisors (Hillhouse)
Zhang Lei
1.4%
NovaBridge Biosciences's share of the portfolio
- Shares
- 5,980,568
- Value
- $11.7M
Latest insider trades
Open-market purchases and sales by NovaBridge Biosciences insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 2026 (view filing)4:05 PM ET | Sep 18 | 3 days | Dennis Phillip AndrewChief Medical Officer | SSale | −8.21K | $0.71 | −$5.83K | −4.5%173.4K after | |
| Sep 11, 2026 (view filing)4:30 PM ET | Sep 9 | 2 days | Cao Sean WuxiongChief Bus. Development Officer | SSale | −108.0K | $0.74 | −$79.9K | −28.8%266.5K after | |
| Sep 1, 2026 (view filing)6:00 PM ET | Aug 31 | 1 day | Xu Cong ClaireEVP, Clinical Development | SSale | −3.28K | $0.79 | −$2.59K | −1.1%304.2K after | |
| Jul 7, 2026 (view filing)7:50 PM ET | Jul 6 | 1 day | Xu Cong ClaireSVP, Clinical Development | SSale | −4.49K | $0.89 | −$3.99K | −1.5%298.1K after | |
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | Dennis Phillip AndrewChief Medical Officer | SSale | −8.49K | $0.66 | −$5.61K | −5.1%157.9K after | |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Xu Cong ClaireSVP, Clinical Development | SSale | −3.49K | $3.94 | −$13.8K | −1.2%290.2K after | |
| May 18, 2026 (view filing) | May 14 | 4 days | Cao Sean WuxiongSee Remarks | SSale | −21.4K | $1.99 | −$42.6K | −37.9%35.1K after | |
| Apr 28, 2026 (view filing) | Apr 24 | 4 days | Hagler Mark ArnoldSee Remarks | PPurchase | +230.0K | $2.51 | +$577.3K | New position230.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in NovaBridge Biosciences at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 5,980,568 | $11.7M | 1.40% | 00.0% | Unchanged |
| Morgan Stanley | 3,653,228 | $7.12M | 0.00% | −184,970−4.8% | Reduced |
| AIHC Capital Management Ltd | 2,878,033 | $5.61M | 5.38% | +615,100+27.2% | Added |
| Siren, L.L.C. | 2,004,739 | $3.91M | 0.08% | −995,261−33.2% | Reduced |
| Marshall Wace, LLP | 1,231,946 | $2.40M | 0.00% | +1,231,946 | New |
| Candriam Luxembourg S.C.A. | 1,132,563 | $2.21M | 0.01% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 1,000,000 | $1.95M | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 851,348 | $1.66M | 0.00% | +851,348 | New |
| Renaissance Technologies LLC | 758,226 | $1.48M | 0.00% | +485,814+178.3% | Added |
| BlackRock, Inc. | 686,208 | $1.34M | 0.00% | +58,712+9.4% | Added |